Observational studyMedicine2025
Effect of immunomodulatory agents on the response to COVID-19 vaccination among patients with neuromuscular diseases: A single center experience.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunomodulatory agents, commonly used in autoimmune neuromuscular disorders, may significantly attenuate immunological response to vaccines. Yet, the degree to which different classes of these drugs suppress the immune system is unclear. This study aimed to characterize the response to the coronavirus disease 2019 (COVID-19) vaccines among our cohort of patients with neuromuscular diseases, including both patients who are and are not receiving immunomodulatory agents. This was a retrospective chart review of our single-center neuromuscular clinic patients who had undergone semi-quantitative COVID-19 antibody testing. A sum of 111 patients were initially identified, and 44 were excluded because of various reasons (e.g., COVID-19 infection, etc). The remaining 67 patients had undergone antibody testing after receiving one of the FDA-approved COVID-19 vaccines (2 doses of Moderna or Pfizer/BioNTech, or 1 of Janssen). A sum of 52 of these patients were receiving immunomodulatory treatments, and 15 were not. Patients were grouped based on their relative antibody response to vaccination, and the antibody responses of patients on each of the different immunomodulatory treatments were compared to those of patients not on any immunomodulation. Patients receiving B-cell depleting therapies demonstrated the weakest response to vaccination (P = .002), and those on mycophenolate mofetil also displayed a weaker response compared to patients not on immunomodulation (P = .045). Corticosteroids (P = .584) and intravenous immunoglobulin (P = .941) had minimal effect on COVID-19 antibody response. The degree to which a specific agent may affect a patient's immune response to vaccines or infections may play a role in a clinician's choice of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.